224 related articles for article (PubMed ID: 30735771)
1. Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.
Yammine L; Kosten TR; Pimenova M; Schmitz JM
Diabetes Res Clin Pract; 2019 Mar; 149():78-88. PubMed ID: 30735771
[TBL] [Abstract][Full Text] [Related]
2. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
Gupta A; Jelinek HF; Al-Aubaidy H
Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
[TBL] [Abstract][Full Text] [Related]
3. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
George C; Byun A; Howard-Thompson A
Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
[TBL] [Abstract][Full Text] [Related]
4. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
5. Newer GLP-1 receptor agonists and obesity-diabetes.
Brown E; Cuthbertson DJ; Wilding JP
Peptides; 2018 Feb; 100():61-67. PubMed ID: 29412833
[TBL] [Abstract][Full Text] [Related]
6. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
Doggrell SA
Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
[TBL] [Abstract][Full Text] [Related]
8. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
9. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
[TBL] [Abstract][Full Text] [Related]
12. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
13. The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.
Pang B; Zhou H; Kuang H
Peptides; 2018 Feb; 100():123-126. PubMed ID: 28807775
[TBL] [Abstract][Full Text] [Related]
14. The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis.
Maciel MG; Beserra BTS; Oliveira FCB; Ribeiro CM; Coelho MS; Neves FAR; Amato AA
Diabetes Res Clin Pract; 2018 Aug; 142():222-235. PubMed ID: 29857094
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong B; Yao Z; Zhou C; Wang W; Sun L; Han J
Eur J Med Chem; 2024 Apr; 269():116342. PubMed ID: 38531211
[TBL] [Abstract][Full Text] [Related]
16. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman JS
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
[TBL] [Abstract][Full Text] [Related]
17. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
Baron HL
J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
[TBL] [Abstract][Full Text] [Related]
18. Obesity and GLP-1 RAs.
Bright T
J Investig Med; 2022 Jan; 70(1):1-2. PubMed ID: 34949727
[No Abstract] [Full Text] [Related]
19. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
20. Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
Kalra S
J Pak Med Assoc; 2014 Mar; 64(3):359-61. PubMed ID: 24864619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
